Cambrex Corporation Announces Appointment Of Shlomo Yanai As Vice Chairman Of The Board Of Directors

Cambrex Corporation Announces Appointment Of Shlomo Yanai As Vice Chairman Of
                            The Board Of Directors

- Former President and CEO of Teva to work with Cambrex team on growth
initiatives -

PR Newswire

EAST RUTHERFORD, N.J., Nov. 29, 2012

EAST RUTHERFORD, N.J., Nov. 29, 2012 /PRNewswire/ --Cambrex Corporation
(NYSE: CBM) announced that Shlomo Yanai was appointed to its Board of
Directorsyesterday and will serve as its Non-Executive Vice Chairman. Mr.
Yanai, who retired in mid-2012 as the President and Chief Executive Officer of
Teva Pharmaceutical Industries Ltd., the largest generic pharmaceutical
manufacturer in the world, has extensive experience in the life sciences
industry. As Vice Chairman of the Cambrex Board, he will work closely with
the Company's other directors and its leadership team to formulate and help
execute Cambrex's growth strategies.

"We are excited to have Mr. Yanai join Cambrex's Board of Directors," said
Chairman John Miller. "Shlomo's exceptional career at Teva positions him well
to make significant contributions to the success of our Company. His in-depth
knowledge of our industry will enhance our ability to build on the progress
we've made and will provide us with valuable insight as we seek and evaluate
growth opportunities."

Cambrex's President and Chief Executive Officer Steven M. Klosk commented,
"Shlomo's outstanding background in the pharmaceutical industry will be a
great asset to us as we continue to implement our strategic initiatives to
grow sales of active pharmaceutical ingredients and finished dosage form
products for the branded and generic markets."

Mr. Yanai served from 2007 until mid-2012 as President and Chief Executive
Officer of Teva Pharmaceutical Industries Ltd., during which time Teva
increased revenues from $8.4 billion to approximately $20 billion. From 2003
to 2006, Mr. Yanai was the President and Chief Executive Officer of Makhteshim
Agan Industries, a leading global agro-chemicals company. Mr. Yanai also
served as a member of the Board of Directors of the Bank Leumi Le-Israel,
Israel's second largest bank, LycoRed Natural Products Industries and I.T.L.
Optronics Ltd. Until his retirement from the Israeli Army in 2001 at the rank
of Major General, Mr. Yanai was the head of the Strategy Planning Branch of
General Headquarters of the Israel Defense Forces. Currently, Mr. Yanai is a
member of the Board of Governors of Technion, the Israel Institute of
Technology and the International Advisory Board, M.B.A. program of Ben-Gurion
University. He is also an honorary member of the Board of The Institute for
Policy and Strategy of the Interdisciplinary Center (IDC), Herzliya.

"The Cambrex team has been very successful in propelling the worldwide growth
of the Company and I am looking forward to contributing to the Company's
initiatives to continue this success," commented Mr. Yanai.

About Cambrex

Cambrex Corporation is an innovative life sciences company that provides
products, services and technologies to accelerate the development and
commercialization of small molecule therapeutics. We offer Active
Pharmaceutical Ingredients (APIs), advanced intermediates and enhanced drug
delivery products for branded and generic pharmaceuticals. Our development and
manufacturing capabilities include enzymatic biotransformations, high potency
APIs, high energy chemical synthesis, controlled substances and formulation of
finished dosage form products. For more information, please visit
www.cambrex.com.

SOURCE Cambrex Corporation

Website: http://www.cambrex.com
Contact: Stephanie LaFiura, Investor Relations Associate, +1-201-804-3037,
stephanie.lafiura@cambrex.com
 
Press spacebar to pause and continue. Press esc to stop.